Chronic Lymphocytic Leukemia

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.